CVA Family Office’s Moleculin Biotech MBRX Stock Holding History

CVA Family Office’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2	Hold	1	–	–	﹤0.01%	1838
2025 Q4	$3	Hold	1	–	–	﹤0.01%	1288
2025 Q3	$18	Hold	1	–	–	﹤0.01%	1297
2025 Q2	$10	Hold	1	–	–	﹤0.01%	1279
2025 Q1	$33	Hold	1	–	–	﹤0.01%	1385
2024 Q4	$58	Hold	1	–	–	﹤0.01%	1281
2024 Q3	$97	Hold	1	–	–	﹤0.01%	1259
2024 Q2	$120	Hold	1	–	–	﹤0.01%	1264
2024 Q1	$201	Hold	1	–	–	﹤0.01%	1044
2023 Q4	$429	Buy	+1	New	+$208	﹤0.01%	1020
2023 Q3	–	Sell	-1	Closed	-$289	–	658
2023 Q2	$289	Hold	1	–	–	﹤0.01%	995
2023 Q1	$480	Hold	1	–	–	﹤0.01%	942
2022 Q4	$530	Hold	1	–	–	﹤0.01%	896
2022 Q3	$1K	Hold	1	–	–	﹤0.01%	852
2022 Q2	$1K	Hold	1	–	–	﹤0.01%	875
2022 Q1	$1K	Hold	1	–	–	﹤0.01%	927
2021 Q4	$1K	Buy	+1	New	+$887	﹤0.01%	880
2021 Q3	–	Sell	-1	Closed	-$2K	–	658
2021 Q2	$2K	Hold	1	–	–	﹤0.01%	888
2021 Q1	$2K	Buy	+1	New	+$1.83K	﹤0.01%	709

Other funds holding MBRX

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EFG International Zurich $4.67B AUM

CVA Family Office's MBRX Position: Q1 2026 in Review

CVA Family Office held its Moleculin Biotech (MBRX) position steady in Q1 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #1838.

CVA Family Office first reported a position in MBRX in Q1 2021 and has held it in 19 quarters since. The position peaked at $2K in Q2 2021. 20 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.

CVA Family Office held 1 share of Moleculin Biotech worth $2 as of Q1 2026.
CVA Family Office left its Moleculin Biotech share count unchanged in Q1 2026.
Moleculin Biotech made up ﹤0.01% of CVA Family Office's portfolio in Q1 2026, its #1838 holding.
CVA Family Office first reported a position in Moleculin Biotech in Q1 2021 and has held it in 19 quarters since.
CVA Family Office's Moleculin Biotech position peaked at $2K in Q2 2021.
20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.